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Smoking and diabetes are the only established risk factors for pancreatic cancer. Findings from recent studies suggest that obesity may
also be associated with an increased risk of pancreatic cancer, but several earlier studies were less conclusive. We examined this
relationship in a meta-analysis of published data. Six case–control and eight cohort studies involving 6391 cases of pancreatic cancer
were identified from a computer-based literature search from 1966 to 2003. The relative risk per unit increase in body mass index
was estimated for each of the studies from the published data. In a random effects model, the summary relative risk per unit increase
in body mass index was 1.02 (95% CI: 1.01–1.03). There was some evidence of heterogeneity between the studies’ results (P¼0.1).
The summary relative risk estimates were slightly higher for studies that had adjusted for smoking and for case–control studies that
had not used proxy respondents. The estimated per unit increase in body mass index would translate into a relative risk of 1.19 (95%
CI: 1.10–1.29) for obese people (30kgm
 2) compared to people with a normal body weight (22kgm
 2). These results provide
evidence that the risk of pancreatic cancer may be weakly associated with obesity. However, the small magnitude of the summary risk
means the possibility of confounding cannot be excluded.
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Pancreatic cancer is the fifth most common cause of cancer
mortality in the European Union and North America and is
responsible for approximately 70000 deaths in these regions
annually (Ferlay et al, 2001). Smoking and diabetes are the only
well-established risk factors for this invariably fatal disease
(Gapstur and Gann, 2001). Smoking, however, is thought to
account for at most 20–40% of pancreatic cancer cases (Interna-
tional Agency for Research on Cancer, 1990). The findings from
several large US cohort studies suggest that obesity (defined as
body mass index of at least 30kgm
 2) may also be a risk factor for
pancreatic cancer (Michaud et al, 2001; Calle et al, 2003). The
results of several earlier observational studies were less conclusive.
The aim of this meta-analysis was to examine the relationship




Epidemiological studies were identified through searches of the
electronic databases MEDLINE (1966–2003), EMBASE (1980–
2003) and the Science Citation Index (1981–2003) and also from
citations in the selected papers and review articles. The key words
that were used for the search were pancreatic cancer, obesity, body
mass index, anthropometric factors and risk factors. The search
was limited to human studies and restricted to peer-reviewed
articles. No language or date limitations were imposed.
Study selection
Each study was required to have published information on the
number of study participants and on age-adjusted or age-matched
relative risks (or odds ratios, subsequently referred to as relative risks),
and their corresponding confidence intervals according to categories
of body mass index or per unit increase in body mass index, or data
that would allow this to be estimated. Details of the boundaries that
were used for the categories of body mass index were also required.
In total, 16 studies were identified in the search of which 14
satisfied the criteria for inclusion. A US case–control study (Lyon
et al, 1993) was not included because the authors only published a
crude relative risk for the top tertile to the lowest tertile of body
mass index, and did not provide any information on the
boundaries for the tertiles. A Chinese case–control study (Ji et al,
1996) was excluded because there is evidence that adiposity-
associated health effects occur at lower levels of body mass index
among Asian populations than among Western populations
(WHO, IASO and IOT, 2000). The studies that were included were
all of either European or North American populations.
Data extraction
For each eligible study, the following information was extracted
independently by two reviewers: country and year of diagnosis of
the cases; study design (cohort or case–control and type of
controls); measured or self-reported weight; at what time point
body weight was assessed; whether proxy respondents had been
used; categories of body mass index; relative risk and 95%
confidence intervals for each category of body mass index;
estimated relative risk per unit increase in body mass index;
adjustment factors used in the analysis. The most fully adjusted
relative risks were extracted from each published article. Received 21 March 2003; revised 29 May 2003; accepted 29 May 2003
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Body mass index was defined as weightheight
 2 in all the studies
except one. Silverman et al calculated body mass index as
weightheight
 1.5 for women only. To translate these categories
of body mass index into weightheight
 2, we divided the body mass
index categories by the square root of height where height was set
to 1.64m, the mean height of women in a large US cohort study
(Michaud et al, 2001).
Only three studies (Friedman and van den Eeden, 1993; Michaud
et al, 2001) had reported results in the form of a relative risk per
unit increase in body mass index. Therefore, for the other studies it
was necessary to estimate the relative risk per unit increase in body
mass index by regressing the risks reported according to categories
of body mass index on the mid-point of each category. This was
done using weighted least squares regression analysis with the
weights taken as the variance of the log relative risk. Adjustment
was made for the lack of independence of risks within each study
(because the risks are all estimated with the same baseline) using a
method for combining nonindependent strata (Berrington and
Cox, 2003). For any open-ended categories of body mass index
(e.g. o25kgm
 2), the mid-points were estimated assuming that
body mass index was normally distributed and by taking the mid-
point between the specified boundary and the estimated first
percentile for estimation of a lower limit or 99th percentile for an
upper limit. A sensitivity analysis was conducted to investigate the
effect of the choice of boundaries on the slope estimates. Two
case–control studies (Howe et al, 1990; Zatonski et al, 1991) only
published mean values for body mass index for cases and controls.
Approximate slope estimates were calculated for these studies
using the method described by Greenland (1987).
Relative risks for each study are plotted as black squares whose
size is inversely proportional to the variance of the logarithm of
the relative risk. Diamonds represent summary relative risks for
the pooled data, calculated using the method of empirically
weighted least squares where the weights are defined as the inverse
of the variance of the log relative risks under a random effects
model (Cox, 1977). All but five of the studies had reported results
for male and female patients separately. The results for Howe et al
were also reported for proxy and nonproxy respondents
separately. To examine other potential sources of variability,
summary results were stratified according to sex and other
study design and adjustment factors. Heterogeneity between
these factors was estimated using a meta-regression model (Ursin
et al, 1995).
RESULTS
Overall six case–control (Bueno de Mesquita et al, 1990; Howe
et al, 1990; Ghadirian et al, 1991; Zatonski et al, 1991; Silverman
et al, 1998; Hanley et al, 2001) and eight cohort studies (Friedman
and van den Eeden, 1993; Shibata et al, 1994; Gapstur et al, 2000;
Michaud et al, 2001; Stolzenberg-Solomon et al, 2002; Calle et al,
2003; Lee et al, 2003) were eligible for inclusion in this meta-
analysis. In total, these studies included 6391 cases of pancreatic
cancer (Table 1). Most of the studies (11) were of North American
populations. Height and weight were measured in three of the
cohort studies and were self-reported in all the other studies. All of
the case–control studies used population-based controls. Four of
the case–control studies used proxy respondents because some of
the cases were too ill to be interviewed.
The estimated increase in relative risk per unit increase in body
mass index for each of the 14 studies is shown in Figure 1
separately for male and female subjects (wherever this information
was available). There was some evidence of heterogeneity between
the estimates (P¼0.1), with 15 of the 22 estimates suggesting a
positive association between body mass index and the risk of
pancreatic cancer and the remainder a negative one. Overall, there
was evidence of a small positive increase in risk per unit increase
in body mass index and the summary relative risk was 1.02 (95%
CI: 1.01–1.03). This per unit increase would be equivalent to a
relative risk of 1.19 (95% CI: 1.10–1.29) for obese people
(30kgm
 2) compared to people with a normal body weight
(22kgm
 2). The results that had the greatest influence on the
summary risk were the female subjects from the study by Howe
(using proxy respondents), and the studies by Stolzenberg-
Solomon and Calle. In particular, if the female patients from the
Howe (proxy respondents) study were excluded, then the summary
relative risk increased to 1.03.
Table 1 Details of the 14 studies included in the meta-analysis








Sex Cases Controls Proxies Smoking Diabetes
Bueno de Mesquita 1990 (Netherlands) C–C 1984–1988 2 years before interview M 90 232 Yes Yes No
F 74 248
Howe 1990 (Canada) C–C 1983–1986 2 years before interview M 141 270 Yes No No
F 108 235
Ghadirian 1991 (Canada) C–C 1984–1988 2 years before interview M, F 179 239 Yes Yes No
Zatonski 1991 (Poland) C–C 1985–1988 Not known M, F 110 195 Yes No No
Friedman 1993 (USA) Cohort 1945–1988 Prospective (measured) M, F 450 2687 NA Yes No
Shibata 1994 (USA) Cohort 1981–1990 Prospective M, F 65 NA NA Yes No
Silverman 1998 (USA) C–C 1986–1989 Usual in adulthood M 218 1231 No Yes Yes
F 213 747
Gapstur 2000 (USA) Cohort 1967–1995 Prospective (measured) M 96 NA NA Yes Yes
F4 3N A
Michaud 2001 (USA) Cohort 1976–1998 Prospective M 140 NA NA Yes Yes
F 210 NA
Hanley 2001 (Canada) C–C 1994–1997 2 years before interview M 173 1074 No Yes No
F 139 1191
Stolzenberg-Solomon 2002 (Finland) Cohort 1985–1997 Prospective (measured) M 172 NA NA NA Yes
Lee 2003 (USA) Cohort 1962–1995 Prospective M, F 212 NA NA NA Yes
Calle 2003 (USA) Cohort 1982–1998 Prospective M 1908 NA NA Yes No
F 1650 NA
NA¼not applicable; C–C¼case–control study; M¼males; F¼females.
Michaud (2001) published the results of two cohort studies in one paper. The male subjects were one cohort study (Health Professionals’ Follow-up study) and the female
subjects were the other (Nurses’ Health Study).
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yFor most of the studies, the risk per unit increase in body mass
index had to be estimated from published data. To assess the
sensitivity of the summary relative risk to the estimation of the
mid-points for the open-ended categories of body mass index (e.g.
o25kgm
 2), the categories were reassigned mid-points that were
5, 10 and 15% below (for the bottom category or above for the top
category) the specified boundary. For example, if the baseline
category was o23kgm
 2, then the category mid-point was set at
21.85, 20.70 and 19.55kgm
 2 and the relative risk per unit increase
in body mass index was recalculated. The overall summary relative
risk was quite insensitive to these changes. The use of 5% above
and below the bottom and top category increased the summary
relative risk to 1.03 (95% CI: 1.01–1.04), whereas 15 and 10% left it
unchanged).
To explore the sources of heterogeneity between the studies, the
relative risk estimates were calculated for subgroups of studies
defined according to various covariates (see Figure 2). The
summary relative risk for a unit increase in body mass index
was marginally higher for male than for female subjects (1.03
compared to 1.02) and also for cohort compared to case–control
studies (1.03 compared to 1.02). The results from the North
American studies were also higher than the European studies (1.02
and 1.00, respectively). Studies in which height and weight had
been measured had a slightly lower summary relative risk (1.02)
than studies in which they had been self-reported (1.03). When we
restricted the studies to those that had adjusted for smoking, the
summary relative risk increased to 1.03. Finally, although diabetes
is now an established risk factor for pancreatic cancer some of the
studies had not adjusted for diabetes. In the six studies that had
made this adjustment, the summary per unit increase in relative
risk was 1.03 compared to 1.02 in the studies that had not adjusted
for diabetes. Tests for heterogeneity between each of these
summary results generally lacked power; however, there was some
evidence of significant differences in the summary relative risk
according to whether an adjustment for smoking had been made
(P¼0.04). Some of the case–control studies had used proxy
respondents if cases were too ill to be interviewed and there was
evidence also of some heterogeneity between these risk estimates
(P¼0.02). In the studies that had used proxy respondents, the
summary relative risk was lower (0.99) than in those that did not
use proxy respondents (1.03).
DISCUSSION
Overall, there was evidence of a small positive increase in the risk
of pancreatic cancer per unit increase in body mass index. A unit
increase in body mass index for a male patient of 1.78m (5ft 10in)
represents weight gain of about 3kg (6.6lbs). For a female patient
of 1.64m (5 feet 5 inches), a unit increase in body mass index
represents weight gain of about 2.5kg (5.5lbs). The observed per
unit increase in relative risk translates into a 19% higher risk of
pancreatic cancer for obese people (body mass index 430kgm
 2)
compared to those of normal body weight (22kgm
 2). There was,
however, some evidence of heterogeneity between the studies’
results (P¼0.1). The summary relative risk estimates were slightly
higher for studies that had adjusted for smoking and for case–
control studies that had not used proxy respondents.
As this meta-analysis was based on published data, there is the
possibility that publication bias could have affected the results.
The relative risks are presented in chronological order of
publication, and there was no visual evidence of publication bias
(Figure 1). Neither was there evidence that the smaller studies
tended to have positive results more frequently. However, it is not
possible to rule out the possibility that further data, which show no
evidence of an association between body mass index and
pancreatic cancer risk, exist but have not been published.
Two case–control studies that had published information on
body mass index and the risk of pancreatic cancer could not be
included in this analysis. A US case–control study of 149 cases of
pancreatic cancer conducted in Utah (Lyon et al, 1993), which was
not included because the authors only published crude relative
risks for the highest to lowest tertile and provided no information
on the tertile boundaries, found a relative risk for the highest
tertile of body mass index compared to the lowest of 0.83 (95% CI:
0.43–1.58) for men and 1.05 (95% CI: 0.53–2.08) for women.
Although the study findings were null, the CI were wide and were
therefore not inconsistent with our summary relative risk of 1.19
for obese people (body mass index 430kgm
 2) compared to
those of normal body weight (22kgm
 2). A Chinese case–control
study (Ji et al, 1996) was not included because there is evidence
Study
(first author)




Bueno de Mesquita    1990   Females         1.01 (0.94 − 1.09)    
Males           0.99 (0.92 − 1.06)    
Howe (nonproxy)     1990   Females         0.95 (0.86 − 1.05)    
Howe (nonproxy)     Males           1.06 (0.95 − 1.19)    
Howe (proxy)         Females         0.98 (0.94 − 1.02)    
Howe (proxy)         Males           0.97 (0.88 − 1.05)    
Ghadirian            1991   Males and females 0.99 (0.93 − 1.05)    
Zatonski             1991   Males and females 1.04 (0.98 − 1.10)    
Friedman             1993   Males and females 1.02 (1.00 − 1.04)    
Shibata              1994   Males and females 1.03 (0.95 − 1.13)    
Silverman            1998   Females         1.04 (0.99 − 1.08)    
Males           1.04 (1.00 − 1.09)    
Gapstur              2000   Females         0.99 (0.91 − 1.07)    
Males           1.11 (1.05 − 1.18)    
Hanley               2001   Females         1.02 (0.98 − 1.07)    
Males           1.05 (1.00 − 1.11)    
Michaud              2001   Females         1.03 (0.99 − 1.07)    
Males           1.05 (0.99 − 1.11)    
Stolzenberg-Solomon 2002   Males           0.97 (0.93 − 1.02)    
Calle                2003   Females         1.03 (1.02 − 1.04)    
Males           1.03 (1.02 − 1.04)    
Lee                  2003   Males and females 1.01 (0.96 − 1.05)    
Summary              1.02 (1.01 − 1.03)    
0.8 0.9 1.0 1.1 1.2
Figure 1 Estimated relative risk and 95% confidence interval (95% CI) of
pancreatic cancer for a unit increase in body mass index.
Group of studies No. of 
studies
Relative risk (95%CI) Relative risk and 95% CI
All                         14   1.02 (1.01 − 1.03)    
Males                        8   1.03 (1.01 − 1.06)    
Females                      7   1.02 (1.00 − 1.03)    
Case−control                 6   1.02 (1.00 − 1.03)    
Cohort                       8   1.03 (1.01 − 1.04)    
North American studies      11   1.02 (1.01 − 1.03)    
European studies             3   1.00 (0.97 − 1.03)    
Measured anthropometry       3   1.02 (0.97 − 1.07)    
Self-reported anthropometry 11   1.03 (1.02 − 1.03)    
Smoking adjustment          11   1.03 (1.02 − 1.03)    
No smoking adjustment        2   1.00 (0.96 − 1.03)    
Diabetes adjustment          6   1.03 (1.00 − 1.06)    
No diabetes adjustment       8   1.02 (1.02 − 1.03)    
Proxies used                 4   0.99 (0.97 − 1.02)    
No proxies used              3   1.03 (1.01 − 1.06)    
0.9 1.0 1.1
Figure 2 Estimated relative risk and 95% confidence interval (95% CI) of
pancreatic cancer for a unit increase in body mass index in different groups
of studies.
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ythat adiposity-associated health effects occur at lower levels of
body mass index among Asian populations than among Western
population (WHO, IASO and IOT, 2000). It was not clear therefore
that a relative risk per unit increase in body mass index would
have the same meaning in an Asian as in a Western population. In
this study, which included 483 cases of pancreatic cancer, there
was evidence of an increasing risk of pancreatic cancer with
increasing body mass index in men (P¼0.05) but not in women
(P¼0.31). The relative risk for the top quartile of body mass index
in male patients (422.4 compared to o19.5kgm
 2) was 1.38
(95% CI: 0.91–2.08) and for female patients, it was 1.46 (95% CI:
0.85–2.51) (423.1kgm
 2 compared to o19.5kgm
 2).
The studies that were included in this meta-analysis contained
91% of the cancer cases that were available and the results from the
two studies that could not be included were not inconsistent with
the findings from this meta-analysis. Two other record linkage
cohort studies of obese individuals both found an elevated risk of
pancreatic cancer compared to expected rates in the general
population of 1.7 and 1.5 (95% CI: 1.1–1.9), respectively (Moller
et al, 1994; Wolk et al, 2001). The study by Wolk et al found that
the risk decreased with age from 2.5 (95% CI: 1.5–4.0) for those
aged o60 years, to 2.0 (1.3–2.8) for 60–69 year olds and 0.7 (0.4–
1.2) for those aged 70þyears.
Smoking and diabetes are both potential confounding factors for
the relationship between obesity and pancreatic cancer. If there is
an association between body mass index and smoking, however, it
is more likely to be a negative one, as current smokers have been
observed to weigh less than nonsmokers (Istvan et al, 1992).
Therefore, ignoring confounding by smoking could make the
association between obesity and pancreatic cancer less positive.
Only two of the studies that were included in this meta-analysis
had not adjusted the risk estimates for smoking (Howe et al, 1990;
Zatonski et al, 1991). When these studies and the cohort study of
smokers (Stolzenberg-Solomon et al, 2002) were excluded, the
summary relative risk per unit increase in body mass index was
slightly higher (1.03). In the cohort study by Calle et al, the risk
associated with obesity was investigated in men and women who
had never smoked. In this subgroup, the relative risk of pancreatic
cancer mortality for a body mass index of 35–39.9kgm
 2 was 2.61
compared to those with a normal body mass index (18.5–
24.9kmm
 2). In the analysis with adjustment for smoking, the
relative risks were somewhat lower at 1.49 for men and 1.41 for
women.
Long-standing diabetes has also been established as a risk factor
for pancreatic cancer with duration of diabetes of 5 years or more
being associated with a two-fold increased risk of pancreatic
cancer (Everhart and Wright, 1995). Hence, a history of diabetes
could positively confound the relationship between the risk of
pancreatic cancer and body mass index. However, in the six
studies in this meta-analysis that had adjusted for a history of
diabetes, the risks associated with a unit increase in body mass
index were actually marginally higher than in the studies that had
not adjusted for this risk factor (1.03 compared to 1.02). In their
case–control study, Silverman et al also published the risks
associated with obesity cross-classified by a history of diabetes.
Although there was evidence of an increase in risk for both those
with and without the disease, within each level of body mass index
diabetics had a higher risk of pancreatic cancer than nondiabetics
(Silverman et al, 1999). Future studies need to examine the
relationship between obesity and pancreatic cancer in more detail
in those who have never smoked and in those without a history of
diabetes.
All of the studies except for Gapstur et al, Friedman et al and
Stolzenberg-Solomon et al relied upon self-reported height and
weight and it is possible that weight may have been under-
reported, especially by overweight or obese individuals (Spencer
et al, 2002). Such under-reporting could result in overestimation of
the dose–response relationship. The summary relative risk
estimate for the studies that had measured anthropometry was
marginally lower than those that relied upon self-reporting (1.02 vs
1.03). In case–control studies, under-reporting of weight could be
a potential bias if it occurred unequally among cases and controls.
Case–control studies could also be biased if the individuals in the
control group were more ‘health conscious’ and thus less likely to
be overweight than the cases. However, the summary relative risks
in the case–control studies (1.02) were actually slightly lower than
those for the cohort studies (1.03).
Obesity may be related to an increased risk of several other
cancers including those of the endometrium, colorectum, oeso-
phagus, kidney and postmenopausal breast cancer (IARC, 2002).
Some of the mechanisms that have been suggested to explain these
relationships may also be relevant for pancreatic cancer, including
the hypothesis that insulin resistance and abnormal glucose
metabolism may be a factor in pancreatic cancer development
(Gapstur et al, 2000). The association between diabetes and
pancreatic cancer risk (Everhart and Wright, 1995) supports this
hypothesis, and further support for this is given by findings that
physical activity may be associated with a decreased risk of
pancreatic cancer (Hanley et al, 2001; Michaud et al, 2001).
This meta-analysis of the available observational data provides
evidence that the risk of pancreatic cancer may increase
slightly with increasing body mass index, and that obese
individuals may have a risk that is 19% higher than those with a
normal body mass index. However, the small magnitude of the
summary relative risk means that the possibility of confounding
cannot be excluded.
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